12.22 USD
▼-0.06-0.49%
盘后 12.16 -0.49%
2026-09-15
市值
$557.98M
市盈率
—
EPS
-4.51
股息率
—
52 周区间
8.75 – 17.82
成交量
146.34K
Beta
—
目标价
37.67
52W 低 8.7552W 高 17.82
价格走势
公司简介
AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company’s product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFβR1 for the treatment of Fibrostenosing Crohn’s disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFβR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 cli...